Electrophysiology (EP) is the branch of science that deals with the study of electric activity in the human body. EP devices are used to treat abnormal electrical properties of cell and tissues that leads to various cardiac arrhythmias. Innovative EP technologies are developed to improve the diagnosis and treatment of life-threatening conditions, such as atrial fibrillation (AF), atrial flutter, Wolff-Parkinson-White Syndrome (WPW), atrioventricular nodal reentry tachycardia (AVNRT), and other cardiac arrhythmias.
The growing incidence of AF-one of the most common heart rhythm disorder or arrhythmia is the prime factor to drive the growth of the EP market. In addition, cardiovascular diseases treatment market is assured to grow on account of unmet clinical needs and upcoming treatment modifications. Increase in baby boomer generation with high-risk of targeted diseases and increase in adoption of EP catheter ablation propels the market growth. Moreover, rise in focus of the key players toward innovative EP technologies (such as 3D mapping systems, novel diagnostic catheters, and laser ablation systems), has fuel the demand for EP devices across various settings in EP labs. However, stringent government regulations, high cost of the advanced EP devices, preference to pharmaceutical interventions (drugs) over EP treatment devices and dearth of skilled & experienced electrophysiologists are set to restrain the market growth. The world electrophysiology market is projected reach $8,271 Million by 2022, growing at a CAGR of 13.4% during 2016 to 2022, from 2015 market value of $3,420 million.
The world electrophysiology market is segmented on the basis of product, indication and geography. Based on product, the market is segmented primarily into EP ablation catheters, EP laboratory devices, EP diagnostic catheters, access devices and others. EP ablation catheter is further sub-segmented into cryoablation EP catheters, radiofrequency EP catheters, microwave EP catheters, laser EP catheters, and navigational advanced mapping accessories. Radiofrequency EP catheters are further categorized into conventional and irrigated-tip ablation catheters. Radiofrequency EP catheters has the largest market share, owing to high prevalence rate of atrial fibrillation and technological advancements in RF ablation such as irrigated tip catheters, which is found to be superior (in terms of efficacy and safety) than conventional RF ablation. Cryoablation EP catheter market is expected to grow at the fastest rate due to technological advancements in this sector and preferred option by the physicians to ablate abnormal cardiac cells, where procedural precision is crucial. In addition, EP X-Ray Systems holds remarkable share in the EP market and poised to grow at steady pace due to the growing demand in EP labs to enhance the ability to perform complex procedures with confidence. Moreover, steerable diagnostic catheters are the driving force behind the growth of conventional EP diagnostic catheters attributed to the rising adoption of these devices gaining FDA approval for the treatment of AF. Based on indication, the market is segmented into atrial fibrillation, atrial flutter, atrioventricular nodal reentry tachycardia (AVNRT), Wolff-Parkinson-white syndrome (WPW) and others. Atrial fibrillation holds the highest share in the indication segment owing to the high incident rate and the most common type of cardiac arrhythmia in clinical practice.
The geographical segmentation of the market includes North America, Europe, Asia-Pacific, and LAMEA. In 2015, North America accounted for the largest market share of 36.2% in the EP market and estimated to retain its dominant position throughout the forecast period. The growth in this region is mainly due to the factors such as product innovations, sophisticated healthcare infrastructure, U.S. ‐ being the target area for the top players in the market owing to high prevalence rate of AF. Nevertheless, Asia Pacific region is expected to emerge as the area with maximum growth potential due to the rising number of cardiovascular diseases, presence of high unmet needs, and increased focus of key players towards emerging markets such as China and India, and increased healthcare spending for the development of improved healthcare infrastructure.
Product development and launch is the mostly adopted strategy in the electrophysiology market followed by acquisition. The report provides a comprehensive analysis of the key players that operate in the world Electrophysiology market such as:
KEY MARKET BENEFITS
KEY MARKET SEGMENTS
The Global Cetirizine Hydrochloride market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) of XX% from between 2016 and 2022. This report studies the global Cetirizine Hydrochloride market, especially in North America, Europe, Asia-Pacific, South America, Middle ...
November 2017 | $4960 |View Details>>
In 2016, the Asia-Pacific Cetirizine Hydrochloride market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Cetirizine Hydrochloride in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, India, Australia, Indonesia, Thailand and Philippines, focuses ...
November 2017 | $4660 |View Details>>
In 2016, the Cetirizine Hydrochloride market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In China market, the top players include UCB Pharma Pfizer J ...
November 2017 | $3360 |View Details>>
In 2016, the Europe Cetirizine Hydrochloride market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Cetirizine Hydrochloride in Europe market, especially in Germany, UK, France, Italy, Russia, Benelux, Turkey and other countries in ...
November 2017 | $4660 |View Details>>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research